Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,712 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: SCHIZOPHRENIA Clear all
Completed Phase 1Phase 2 Interventional

Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia

NCT01292577
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CET/PT, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 17, 2026, 4:11 PM EDT
Terminated Not applicable Interventional Results available

Functional Rehabilitation for Older Patients With Schizophrenia

NCT00712075
View directory record Official record
Conditions
Schizophrenia, Aging
Interventions
CBSST+PDA, Cognitive Behavioral Social Skills Training, PDA-only
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
45 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Results available

Multicenter, Open-label, Safety and Tolerability Study

NCT01649557
View directory record Official record
Conditions
Schizophrenia
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 17, 2026, 4:11 PM EDT
Terminated Phase 3 Interventional Results available

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

NCT00257192
View directory record Official record
Conditions
Schizophrenia
Interventions
placebo, Ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
46
States / cities
Birmingham, Alabama • San Diego, California • Stanford, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 17, 2026, 4:11 PM EDT
Completed No phase listed Observational

Side Effects of Antipsychotic Medications

NCT00363181
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 66 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Not applicable Interventional Results available

MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications

NCT01953237
View directory record Official record
Conditions
Schizophrenia
Interventions
MedActive, Smartphone
Behavioral · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

NCT00492336
View directory record Official record
Conditions
Schizophrenia
Interventions
rasagiline (Pharmacodynamics), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 17, 2026, 4:11 PM EDT
Terminated Phase 2Phase 3 Interventional

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192
View directory record Official record
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness

NCT03062267
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Mobile Interventionist
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

NCT02624167
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
NW-3509A, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Garden Grove, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 17, 2026, 4:11 PM EDT
Terminated Phase 4 Interventional Results available

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

NCT03643159
View directory record Official record
Conditions
Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
Interventions
Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
Combination Product · Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Not applicable Interventional

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

NCT01878513
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
Interventions
risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 2Phase 3 Interventional

Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia

NCT00430560
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
cognitive rehabilitation, work therapy, work therapy
Behavioral · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients

NCT01086748
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Placebo, LY2140023
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Escondido, California • Garden Grove, California • Paramount, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Not applicable Interventional

Is Cognitive Training an Option?

NCT05352568
View directory record Official record
Conditions
Schizophrenia, Schizoaffective, Cognition
Interventions
Cognitive Training
Behavioral
Lead sponsor
Alliant International University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 17, 2026, 4:11 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Perceptual Deficits in Schizophrenia

NCT02337439
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sensory Information Processing Training, Active Control Training
Behavioral
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

SB-773812 Administered In Adults With Schizophrenia

NCT00259870
View directory record Official record
Conditions
Schizophrenia
Interventions
SB-773812, Olanzapine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

Cognitive Therapy for Negative Symptoms and Functioning

NCT00350883
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Therapy, Treatment as Usual
Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 17, 2026, 4:11 PM EDT
Not yet recruiting Phase 2 Interventional

Brain Imaging of DSP-2342

NCT07850102
View directory record Official record
Conditions
SCHIZOPHRENIA 1 (Disorder)
Interventions
DSP-2342
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Not applicable Interventional

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

NCT00161031
View directory record Official record
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Individuals With Severe Mental Illness

NCT00078741
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Schizophrenia
Interventions
Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Charleston, South Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00706654
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
39
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 4:11 PM EDT
Completed Phase 3 Interventional

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

NCT01192867
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Antipshychotics (Standard of Care)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 17, 2026, 4:11 PM EDT